Group 1 - The company Jilin Changlong Pharmaceutical (08049) announced a subscription to a financial product from the Industrial and Commercial Bank of China, amounting to 50 million RMB [1]

Group 1 - The company Jilin Changlong Pharmaceutical (08049.HK) announced a subscription to a financial product from the Industrial and Commercial Bank of China, amounting to RMB 50 million [1]

吉林省輝南長龍生化藥業股份有限公司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 須予披露交易 認購理財產品 吉林省輝南長龍生化藥業股份有限公司（「本公司」）董事會欣然宣佈，於2025年8月 21日，本公司向中國工商銀行認購理財產品，金額人民幣5,000萬元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 上市規則的涵義 由於根據GEM上市規則第19.22條合併計算的有關中國工商銀行認購事項各自的適用 百分比率超過5%但低於25%，故根據GEM上市規則第19章，中國工商銀行認購事項 構成須予披露交易，因此須遵守GEM上市規則第19章項下的申報及公告規定，惟獲豁 免遵守股東批准之規定。 –1– 中國工商銀行認購事項 有關中國工商銀行理財產品條款的進一步詳情如下： 「如意人生天天鑫核心優選同業存單」理財產品 認購 ...

Core Insights - Jilin Changlong Pharmaceutical (08049) reported a revenue of 439 million RMB for the six months ending June 30, 2025, representing a year-on-year growth of 11.6% [1] - The profit attributable to shareholders was 103 million RMB, showing a slight decline of 1.2% compared to the previous year [1] - The basic earnings per share stood at 18.38 cents [1] Financial Performance - The gross margin for the period was approximately 82.4%, which is an increase compared to the period ending June 30, 2024 [1] - The board attributes the improved gross margin to a reduction in production and material costs [1]

Core Viewpoint - Jilin Changlong Pharmaceutical (08049) reported a revenue of 439 million RMB for the six months ending June 30, 2025, representing an 11.6% year-on-year increase, while the profit attributable to shareholders decreased by 1.2% to 103 million RMB [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 439 million RMB, up 11.6% compared to the same period last year [1] - Profit attributable to shareholders was 103 million RMB, reflecting a decline of 1.2% year-on-year [1] - Basic earnings per share were 18.38 cents [1] Margins and Costs - The gross margin for the period was approximately 82.4%, which is an increase compared to the period ending June 30, 2024 [1] - The board attributes the improved gross margin to a reduction in production and material costs [1]

Financial Performance - The company reported a revenue of RMB 438,869,000 for the six months ended June 30, 2025, representing a 11.7% increase from RMB 393,093,000 in the same period of 2024[5] - Gross profit for the same period was RMB 361,645,000, up from RMB 315,079,000, indicating a growth of 14.8%[5] - Operating profit decreased slightly to RMB 123,803,000 from RMB 127,806,000, a decline of 3.1%[5] - Profit attributable to shareholders was RMB 103,006,000, compared to RMB 104,282,000 in the previous year, reflecting a decrease of 1.2%[5] - Basic earnings per share for the first half of 2025 was 18.38 cents, down from 18.61 cents in the same period of 2024[5] - For the six months ended June 30, 2025, total revenue was RMB 448,640,000, an increase of 6.4% from RMB 423,209,000 in the same period of 2024[13] - Pharmaceutical sales accounted for RMB 438,869,000, up from RMB 393,093,000, reflecting a growth of 11.7% year-over-year[13] - The net profit attributable to shareholders for the same period was RMB 103,006,000, a decrease of RMB 1,276,000 from RMB 104,282,000 in 2024[34] - The gross margin for the six months ended June 30, 2025, was approximately 82.4%, an increase from the previous year's margin due to reduced production and material costs[34] Assets and Liabilities - Total assets as of June 30, 2025, were RMB 1,773,067,000, an increase from RMB 1,670,437,000 at the end of 2024[7] - Current assets increased to RMB 1,328,317,000 from RMB 1,099,048,000, showing a growth of 20.9%[6] - The company’s cash and cash equivalents rose significantly to RMB 485,117,000 from RMB 235,846,000, marking an increase of 105.5%[6] - Total equity increased to RMB 1,732,620,000 from RMB 1,629,614,000, reflecting a growth of 6.3%[7] - Inventory as of June 30, 2025, was valued at RMB 87,175,000, an increase of 45.2% from RMB 59,971,000 at the end of 2024[26] - Trade receivables totaled RMB 269,335,000, a decrease of 3.5% from RMB 279,121,000 at the end of 2024[28] - Bank borrowings remained unchanged at RMB 72,000,000 for both June 30, 2025, and December 31, 2024[29] - Trade payables increased to RMB 66,064,000 as of June 30, 2025, compared to RMB 63,541,000 at the end of 2024, reflecting a rise of 3.9%[30] Operational Highlights - The company continues to focus on the production and distribution of biochemical drugs under the Changlong and Shendi brands in China[10] - Operating profit for the six months ended June 30, 2025, was impacted by depreciation expenses of RMB 13,170,000, compared to RMB 10,902,000 in 2024, indicating a rise of 20.8%[15] - The income tax expense for the period was RMB 19,856,000, a decrease of 12.4% from RMB 22,711,000 in 2024, with a consistent tax rate of 15%[17] - The company expanded production capacity with the completion of a small-volume injection workshop that passed GMP compliance checks[35] - New equipment for traditional Chinese medicine extraction was added, expanding production capacity and range[37] - The company has commercialized new products including alpha-lipoic acid injection and furosemide injection, enhancing its product offerings[37] Corporate Governance - The audit committee, established on May 24, 2001, consists of three independent non-executive directors, responsible for reviewing and supervising the company's financial procedures and internal control systems[53] - The company has adopted a code of conduct for securities trading by directors, which meets or exceeds the standards set by GEM Listing Rules[51] - The board of directors has not fully complied with the corporate governance code regarding the separation of the roles of chairman and CEO, as the same individual holds both positions[52] - The company has not disclosed any non-compliance with the trading standards and code of conduct for directors[51] - The audit committee has reviewed the accounting standards and practices adopted by the company, including the unaudited results for the period ending June 30, 2025[53] - The company has a remuneration policy that considers market conditions and individual employee performance, with discretionary bonuses awarded based on contributions[54] - The chairman, Zhang Hong, is also a major shareholder and has extensive industry experience, contributing to the company's growth and profitability[52] - The company has not reported any interests in competing businesses from its directors or major shareholders during the review period[50] Workforce - As of June 30, 2025, the company employed 798 staff members, an increase from 678 staff members as of June 30, 2024, indicating a growth of approximately 17.7% in workforce size[54] Dividends and Shareholder Actions - The company did not declare an interim dividend for the six months ended June 30, 2025, consistent with the previous year[20] - The company has not repurchased, sold, or redeemed any of its listed shares during the six-month period ending June 30, 2025[55]

Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 中期業績公告 截至二零二五年六月三十日止六個月 香 港 聯 合 交 易 所 有 限 公 司（「聯 交 所」）GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小 型 公 司 提 供 一 個 上 市 的 市 場。有 意 投 資 者 應 了 解 投 資 於 該 等 公 司 的 潛 在 風 險， 並 應 經 過 審 慎 周 詳 的 考 慮 後 方 作 出 投 資 決 定。 由 於GEM上 市 公 司 一 般 為 中 小 型 公 司，在GEM買賣的證券可能會較於聯交所 主 板 買 賣 的 證 券 承 受 較 大 的 市 場 波 動 風 險，同 時 無 法 保 證 在GEM買賣的證券 會 有 高 流 通 量 的 市 場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 會 就 因 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 佈 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 董事會會議通告 吉 林 省 輝 南 長 龍 生 化 藥 業 股 份 有 限 公 司（「本公司」）之 董 事 會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 五 年 八 月 十 四 日（星 期 四）上 午 十 時 假 座 中 華 人 民 共 和 國（「中 國」）吉 林 省 通 化 市 輝 南 縣 朝 陽 鎮 經 濟 開 發 區 舉 行，以 便： 承董事會命 吉林省輝南長龍生化藥業股份有限公司 吉林省輝南長龍生化藥業股份有限公司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 主 席 張 弘 1. 考 慮 及 批 准 本 公 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 吉林省輝南長龍生化藥業股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08049 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 172,500,000 | RMB | | | 0.1 RMB | | 17,250,000 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 172,500,000 | RMB | | | 0.1 RMB | | 17,250,000 | | 2. ...

Financial Performance - The total revenue for the year ended December 31, 2024, was approximately RMB 881,157,000, an increase of 4.7% from RMB 841,545,000 in the previous year[18]. - Profit attributable to owners of the Company increased to RMB 184,250,000 from RMB 148,207,000, representing a growth of 24.3%[18]. - Basic earnings per share rose to RMB 32.89 cents, up from RMB 26.45 cents, marking an increase of 24.5%[18]. - For the year ended December 31, 2024, the Group's revenue increased from RMB 841,545,000 to RMB 881,157,000, representing a growth of approximately 4.7%[38]. - The profit attributable to owners of the Company for the year increased from RMB 148,207,000 to RMB 184,250,000, reflecting a growth of about 24.3%[38]. - Basic earnings per share rose from RMB 26.45 cents last year to RMB 32.89 cents, an increase of approximately 24.4%[38]. - The Group recorded a revenue of approximately RMB 881,157,000 for the year ended December 31, 2024, an increase of 4.4% from RMB 841,545,000 in the previous year[65]. - Profit before income tax for 2024 was RMB 207,160,000, up from RMB 198,314,000 in 2023, indicating a growth of 4.4%[138]. - The profit attributable to owners of the Company for the year was RMB 184,250,000, compared to RMB 148,207,000 in 2023, reflecting a significant increase of 24.3%[138]. Market Strategy and Operations - The Company focused on maintaining market share for its leading product, Hai Kun Shen Xi Jiao Nang, while exploring new markets[20]. - The management emphasized enhancing sales through academic collaborations and participation in national nephrology conferences to stabilize clinical sales[20]. - The Company successfully navigated challenges such as market downturns and policy adjustments, achieving the goals set at the beginning of the year[19]. - Strong leadership and timely decisions from management were highlighted as key factors in the Company's performance[19]. - The Company aims to leverage its competitive advantages for new achievements in the coming years[19]. - The focus on drug quality and market sales orientation was emphasized as a strategy for future development[19]. - The Company emphasized sales and distribution to ensure steady growth of dominant products, particularly in injectable varieties[66]. Research and Development - The Company reported 22 drugs passing the consistency evaluation, with 10 drugs receiving drug registration approvals and 3 new drugs signed during the year[23]. - The Company strengthened its new drug research and development efforts, collaborating with multiple domestic pharmaceutical universities and institutions[23]. - The Group invested approximately RMB 37,324,000 in research and development projects during the year[57]. - The Company deployed a microscopic inspection system in its R&D and testing center, laying the groundwork for the development of traditional Chinese medicine varieties[64]. - New extraction equipment was added in the Traditional Chinese Medicine Extraction Workshop II, expanding production capacity and range[58]. - Thioctic Acid Injection, Furosemide Injection, Urapidil Hydrochloride Injection, and Levocarnitine API obtained registration approvals and have been put into commercial production, enriching the Company's product portfolio[59]. Financial Management and Investments - The expected annualized rate of return for wealth management products subscribed during the year was around 2%–2.5%, compared to 2.5%–3.25% in 2023[39]. - The Company held Wealth Management Products totaling approximately RMB93,265,000, with unrealized gains on fair value change amounting to approximately RMB3,265,000[43][44][45][50]. - The expected annualized return rates for the Wealth Management Products ranged from 2.00% to 2.5%, with the total initial investments being RMB90,000,000[44]. - The Group's investment in time deposits as of December 31, 2024, amounted to approximately RMB1,258,656,000, an increase from RMB937,003,000 in 2023[50]. - The subscriptions of Wealth Management Products were aimed at maximizing the utilization of surplus cash while maintaining high liquidity and low risk, with no losses experienced on these products as of December 31, 2024[47][51]. - The management has shifted investment strategies towards time deposits due to a decrease in principal guaranteed Wealth Management Products and an increase in long-term time deposit returns[48][51]. - A Risk Management Committee has been established to enhance the assessment and management of investments in Wealth Management Products and time deposits[49][52]. - The gain realized from Wealth Management Products for the year ended December 31, 2024, was approximately RMB3,265,000, compared to RMB608,000 in 2023[50][52]. - The Company will continue to seek opportunities to invest idle cash in appropriate Wealth Management Products to enhance overall earnings in the long run[47][51]. - The total unrealized gains on fair value change from Wealth Management Products represented approximately 0.79% to 1.66% of the Group's total assets as of December 31, 2024[44]. - The management considers the subscriptions to Wealth Management Products to be fair and reasonable, benefiting the Group and its shareholders[47][51]. Corporate Governance and Structure - The Company does not recommend the payment of a final dividend for the year[126]. - The Group's principal activity remains the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC[123]. - There were no changes in the nature of the Group's principal activities during the year[123]. - The Group's revenue is entirely generated from sales in the PRC, with all identifiable assets located in the PRC[124]. - As of December 31, 2024, the company's distributable reserves amounted to approximately RMB 1,404,720,000, an increase from RMB 1,244,158,000 in 2023[148]. - The group sold about 9.92% of its goods to its five largest customers in the year, up from 5.5% in 2023, with the largest customer accounting for 2.99% of total sales[149]. - Purchases from the five largest suppliers accounted for approximately 31.6% of total purchases, an increase from 28% in 2023, with the largest supplier representing 9.54% of total purchases[149]. - The group had no future plans for material investments or significant changes in capital assets of subsidiaries and affiliated companies as of December 31, 2024[142]. - The group's operations were primarily financed by shareholders' equity, with a treasury policy of placing cash in interest-bearing deposits[145]. - The group did not employ any financial instruments for hedging purposes due to minimal foreign exchange exposure[158]. - There were no capital commitments or material contingent liabilities as of December 31, 2024[159][160]. - The directors and supervisors of the company have service contracts or letters of appointment for a term of three years[168]. - The group did not purchase, sell, or redeem any of its listed securities during the year[170]. - No directors had a significant beneficial interest in any contracts of significance to the business of the group during the year[169]. - The Company has no provisions for pre-emptive rights under its articles of association or PRC laws[190]. - The Audit Committee reviewed the financial reporting procedures and internal control systems of the Group[193]. - The Company did not grant any rights to acquire shares to directors, supervisors, or chief executives during the year[181]. - The summary of the Group's results and assets for the last five financial years is available on page 124 of the annual report[195]. - The Company has no competing interests from its directors or significant shareholders[189]. Employee and Corporate Culture - The company has a total of 745 employees, with remuneration based on market conditions and individual performance[82]. - The company is committed to enhancing corporate culture and employee welfare to boost morale and teamwork[31]. - The company is committed to maintaining high environmental and social standards to ensure sustainable development[86].